rasagiline has been researched along with Neurodegenerative Diseases in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolognesi, ML; Cavalli, A; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tumiatti, V | 1 |
| Amoroso, R; Carradori, S; De Filippis, B; Fantacuzzi, M | 1 |
| Maruyama, W; Naoi, M; Shamoto-Nagai, M | 1 |
| Alonso, N; Caamaño, O; Cordeiro, MN; García-Mera, X; González-Díaz, H; Luan, F; Romero-Duran, FJ; Yañez, M | 1 |
| Klivényi, P; Rákóczi, K; Vécsei, L | 1 |
| Campagna, F; Carotti, A; Catto, M; Leonetti, F; Nicolotti, O; Pisani, L; Stefanachi, A | 1 |
| Fridkin, M; Youdim, MB; Zheng, H | 2 |
| Eilam, R; Eliash, S; Shteter, N | 1 |
| Amit, T; Bar-Am, O; Weinreb, O; Youdim, MB | 1 |
7 review(s) available for rasagiline and Neurodegenerative Diseases
| Article | Year |
|---|---|
Multi-target-directed ligands to combat neurodegenerative diseases.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium Channel Blockers; Chelating Agents; Cholinesterase Inhibitors; Humans; Huntington Disease; Ligands; Multiple Sclerosis; Neurodegenerative Diseases; Neurofibrillary Tangles; Neurotransmitter Agents; Parkinson Disease; Plaque, Amyloid | 2008 |
Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy.
Topics: Humans; Neurodegenerative Diseases; Polyphenols; Resveratrol; Stilbenes; Structure-Activity Relationship | 2022 |
Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies.
Topics: alpha-Synuclein; Glial Cell Line-Derived Neurotrophic Factors; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Neuroprotection; Neuroprotective Agents; Proto-Oncogene Proteins c-bcl-2; Selegiline; Synucleinopathies | 2022 |
[Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].
Topics: Animals; Creatine; Dopamine Agonists; Glatiramer Acetate; Humans; Indans; Kynurenic Acid; Micronutrients; Nerve Degeneration; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Peptides; Selegiline; Tocopherols; Ubiquinone | 2009 |
Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases.
Topics: Adenosine A2 Receptor Antagonists; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory Agents; Antioxidants; Chelating Agents; Cholinesterase Inhibitors; Drug Design; Drug Discovery; Free Radical Scavengers; Humans; Indans; Ligands; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Nitric Oxide Synthase | 2011 |
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Brain; Chelating Agents; Cholinesterase Inhibitors; Cholinesterases; Culture Media, Serum-Free; Dementia; Dopamine; Dose-Response Relationship, Drug; Humans; Indans; Iron; Lewy Bodies; MAP Kinase Signaling System; Models, Chemical; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Neurons; Piperazines; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Quinolines | 2005 |
Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy.
Topics: Animals; Brain-Derived Neurotrophic Factor; Glial Cell Line-Derived Neurotrophic Factor; Humans; Indans; Neurodegenerative Diseases; Neuroprotective Agents | 2007 |
3 other study(ies) available for rasagiline and Neurodegenerative Diseases
| Article | Year |
|---|---|
TOPS-MODE model of multiplexing neuroprotective effects of drugs and experimental-theoretic study of new 1,3-rasagiline derivatives potentially useful in neurodegenerative diseases.
Topics: Animals; Computer Simulation; Databases, Pharmaceutical; Drug Discovery; Humans; Indans; Models, Biological; Neurodegenerative Diseases; Neuroprotective Agents; Quantitative Structure-Activity Relationship | 2013 |
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Topics: Animals; Brain; Drug Delivery Systems; In Vitro Techniques; Indans; Iron Chelating Agents; Male; Mitochondria; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Neuroprotective Agents; Pargyline; Parkinson Disease; Piperazines; Propylamines; Quinolines; Rats; Rats, Sprague-Dawley | 2004 |
Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension; Indans; Male; Monoamine Oxidase Inhibitors; Nerve Degeneration; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Paraventricular Hypothalamic Nucleus; Rats; Rats, Inbred SHR; Rats, Wistar; Third Ventricle; Treatment Outcome; Vasopressins | 2005 |